Search clinical trials for: linagliptin placebo

Total 53959 results

Merck Sharp & Dohme LLC

Completed

Monotherapy Study in Patients With Type 2 Diabetes Mellitus (0431-021)

Diabetes Mellitus, Type 2
Merck Sharp & Dohme LLC

Completed

MK0431 (Sitagliptin) Pioglitazone Add-on Study for Patients With Type 2 Diabetes Mellitus (0431-055)(COMPLETED)

Type 2 Diabetes Mellitus
Baylor College of Medicine
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Completed

A Pilot Study to Assess the Glucose Lowering Effect of Metformin and Sitagliptin in Adolescents With Type 1 Diabetes

Type 1 Diabetes

United States
Merck Sharp & Dohme LLC

Completed

Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus (0431-020)(COMPLETED)

Diabetes Mellitus, Type II
Merck Sharp & Dohme LLC

Completed

Efficacy and Safety of Sitagliptin/Metformin Fixed-Dose Combination (FDC) Compared to Glimepiride in Participants With Type 2 Diabetes Mellitus (MK-0431A-202)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

Safety and Efficacy of Sitagliptin Compared With Glimepiride in Elderly Participants With Type 2 Diabetes Mellitus (MK-0431-251)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Terminated

A Study of the Efficacy and Safety of MK-0431D (a Fixed-dose Combination of Sitagliptin and Simvastatin) for the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Metformin Monotherapy (MK-0431D-266)

Type 2 Diabetes Mellitus
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Study of TQ-F3083 Capsules in Subjects With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

China
Universidad de Guanajuato
Hospital Regional de Alta Especialidad del Bajio

Completed

Linagliptin in Post-renal Transplantation

Transplanted Kidney Complication
Woman's
Merck Sharp & Dohme LLC

Completed

Sitagliptin + Metformin Compared to Metformin Monotherapy and Placebo in Women With a Recent GDM

Disorder of Glucose Regulation

United States
Lawson Health Research Institute
The Physicians' Services Incorporated Foundation

Terminated

Sitagliptin for the Treatment of Non-alcoholic Steatohepatitis in Patients With Type 2 Diabetes

Type 2 Diabetes | Nonalcoholic Steatohepatitis

Canada
Washington University School of Medicine
The Campbell Foundation

Completed

Dipeptidyl Peptidase-4 Inhibition and Immune Function in HIV (DPPIVinHIV)

Diabetes | Insulin Resistance

United States
National Taiwan University Hospital

Unknown

Effect of Sitagliptin in Impaired Glucose Tolerance

Impaired Glucose Tolerance

Taiwan
University of Minnesota

Completed

Sitagliptin Therapy to Improve Outcomes After Islet Autotransplant

Diabetes | Pancreatitis

United States
Laval University
Merck Sharp & Dohme LLC

Completed

Effects of Sitagliptin on Postprandial Lipemia in Men With Type 2 Diabetes

Diabetes Mellitus | Postprandial Lipemia

Canada
Merck Sharp & Dohme LLC

Completed

Randomized Sitagliptin Withdrawal Study (MK-0431-845)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

30-Week Extension to an Initial Combination Study (24 Weeks in Duration) of Sitagliptin With Pioglitazone (0431-064)

Type 2 Diabetes Mellitus
AstraZeneca
Eli Lilly and Company

Completed

A Comparison of Adding Exenatide With Switching to Exenatide in Patients With Type 2 Diabetes Experiencing Inadequate Glycemic Control With Sitagliptin Plus Metformin

Type 2 Diabetes Mellitus

Korea, Republic of, Mexico, Germany, Greece, Argentina, India, Australia
Biogen

Terminated

Study of Natalizumab in Relapsed/Refractory Multiple Myeloma

Multiple Myeloma

United States
Merck Sharp & Dohme LLC

Completed

Study to Assess Safety & Efficacy of Sitagliptin as Initial Oral Therapy for Treatment of Type 2 Diabetes Mellitus in Pediatric Participants. (MK-0431-083)

Diabetes Mellitus | Type 2 Diabetes
Merck Sharp & Dohme LLC

Completed

Initial Combination With Pioglitazone Study (0431-064)

Type 2 Diabetes Mellitus
Emory University
Boston Medical Center; Rush University; University of Denver

Completed

Linagliptin Inpatient Trial

Type 2 Diabetes

United States
University of Nebraska

Terminated

Using Sitagliptin as a Treatment to Prevent New Onset Diabetes After Kidney Transplantation

End Stage Renal Disease | Type 2 Diabetes

United States
Laval University
Merck Sharp & Dohme LLC

Completed

Sitagliptin Therapy and Kinetics of Inflammatory Markers

Type 2 Diabetes Mellitus

Canada
Georgetown University
Merck Sharp & Dohme LLC

Terminated

Januvia (Sitagliptin) in Healing Chronic Diabetic Foot Ulcers

Type II Diabetes

United States
University of California, San Diego

Completed

Sitagliptin Versus Placebo in the Treatment of Non-alcoholic Fatty Liver Disease

Non-alcoholic Fatty Liver Disease

United States
Laval University
Merck Sharp & Dohme LLC

Completed

Sitagliptin and Kinetics of Triglyceride-rich Lipoproteins Apolipoprotein B48 and B100 in Patients With Type 2 Diabetes (JANUB48)

Type 2 Diabetes Mellitus

Canada
Michael A. Nauck

Completed

Quantification of the Dipeptidyl Peptidase (DPP)-4 Inhibition-mediated Enhancement of the Activity of the Entero-insular Axis

Diabetes

Germany
Mayo Clinic

Completed

Incretins in Impaired Fasting Glucose

Pre-diabetes

United States
Profil Institut für Stoffwechselforschung GmbH
Merck Sharp & Dohme LLC

Completed

Sitagliptin and the Risk for Hypoglycaemia in Type 2 Diabetes Patients

Pharmacological Action

Germany
Vanderbilt University
National Heart, Lung, and Blood Institute (NHLBI)

Completed

The Effect of Dipeptidyl Peptidase 4 Inhibition on Growth Hormone Secretion in Women With Polycystic Ovarian Syndrome

Polycystic Ovary Syndrome

United States
Novo Nordisk A/S

Completed

Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin and/or TZD in Subjects With Type 2 Diabetes (SUSTAIN™ 2)

Diabetes Mellitus, Type 2 | Diabetes

India, Japan, Russian Federation, Spain, Sweden, Argentina, Hungary, Norway, South Africa, Turkey, Bulgaria, Romania, Thailand, Portugal, Hong Kong, Mexico, Ukraine, Czechia
Ingrid Jazet
Merck Sharp & Dohme LLC

Completed

Sitagliptin and Brown Adipose Tissue (Sita01)

Neoplasms, Adipose Tissue

Netherlands
Washington University School of Medicine

Completed

Effectiveness of Sitagliptin for HIV Insulin Resistance and Inflammation

Inflammation | Cardiovascular Disease | Macrophage Infiltration

United States
University Health Network, Toronto
Merck Frosst Canada Ltd.

Completed

Sitagliptin Regulation of Intestinal and Hepatic Lipoprotein Particle and Hepatic Glucose Production in Humans

Hyperlipidemia

Canada
Research Clinical Centre of the Russian Railways...

Unknown

Glucose Variability With DPP-4 Inhibition

Type 2 Diabetes
Khoo Teck Puat Hospital

Completed

Roux-en-Y Gastric Bypass for BMI 27-32 Type 2 Diabetes Versus Best Medical Treatment

Type II Diabetes in Subjects BMI 27 to 32

Singapore
University Hospital, Gentofte, Copenhagen

Completed

GA 6: The Blood Glucose-lowering Effect of Glucose-dependent Insulinotropic Polypeptide

Type2 Diabetes

Denmark
Eli Lilly and Company
Berry Consultants; United BioSource, LLC; Tessella Inc.

Completed

A Study of LY2189265 Compared to Sitagliptin in Participants With Type 2 Diabetes Mellitus on Metformin

Diabetes Mellitus, Type 2

United States, Korea, Republic of, Russian Federation, Puerto Rico, Romania, Spain, Taiwan, Mexico, France, Germany, India, Canada, Poland
Boehringer Ingelheim
Eli Lilly and Company

Completed

Ascertainment of EMR-based Clinical Covariates Among Patients Receiving Oral and Non-insulin Injected Hypoglycemic Therapy

Diabetes Mellitus, Type 2

United States
Boehringer Ingelheim

Completed

Efficacy and Safety of B I1356 (Linagliptin) vs. Placebo Added to Metformin Background Therapy in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Czech Republic, Finland, Greece, India, Israel, Mexico, New Zealand, Russian Federation, Sweden
Daiichi Sankyo, Inc.

Completed

12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin

Type 2 Diabetes Mellitus

United States, Canada
Fayoum University
Boehringer Ingelheim

Completed

Contrast Nephropathy in Type 2 Diabetes (VCG4)

Diabetes | Microalbuminuria | Kidney Function Affection Upon Exposure to Radiocontrast

Egypt
Novo Nordisk A/S

Completed

Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes (PIONEER 3)

Diabetes Mellitus, Type 2 | Diabetes

United States, India, Israel, Japan, Russian Federation, United Kingdom, France, Mexico, South Africa, Turkey, Argentina, Germany, Romania, Brazil, Ukraine
University of Pennsylvania
Children's Hospital of Philadelphia

Completed

Effect of Chronic Incretin-based Therapy in Cystic Fibrosis

Cystic Fibrosis | Pancreatic Insufficiency

United States
Dong-A ST Co., Ltd.

Completed

A Study to Evaluate the Safety, Tolerability, PK and PD of DA-1241 in Healthy Male Subjects and Subjects With T2DM

Diabetes Mellitus, Type 2

United States
Novartis Pharmaceuticals

Completed

Clinical Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LEZ763

Type II Diabetes

United States
Blandine Laferrere
Merck Sharp & Dohme LLC

Completed

Treatment of Diabetes After Gastric Bypass With Sitagliptin (LAF33)

Type 2 Diabetes Mellitus

United States
Kathleen Dungan

Terminated

Use of Sitagliptin for Stress Hyperglycemia or Mild Diabetes Following Cardiac Surgery

Hyperglycemia | Diabetes Mellitus, Type 2

United States
University of Missouri-Columbia

Terminated

Use of Sitagliptin to Decrease Microalbuminuria

Type 2 Diabetes | Microalbuminuria

United States

Search clinical trials for: linagliptin placebo

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United Kingdom

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations